Jagsonpal Pharmaceuticals Buyback 2026 vs Nectar Lifesciences Buyback 2025

Note:

• Small Shareholders are retail shareholders under SEBI regulations.

• General Category includes all other eligible shareholders.

• Entitlement ratio is based on fully paid-up equity shares held on the record date.

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

• Return surplus funds to shareholders and enhance overall shareholder returns.
• Improve financial ratios such as earnings per share and return on equity.

• The buyback will help the company to return surplus cash to its shareholders holding equity shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders.
• The buyback will help the company to optimize the capital structure;
• The Buyback, which is being implemented through the Tender Offer route as prescribed under the SEBI Buyback Regulations, would involve allocation of the number of equity shares as per their entitlement or 15% of the number of equity shares to be bought back, whichever is higher, reserved. The company believes that the reservation for small shareholders would benefit a large number of the Company's public shareholders, who get classified as "Small Shareholders, as per regulations 2(i)(n) of the SEBI Buyback Regulations.
• The buyback may help in improving financial ratios like earnings per share, return on capital employed, and return on equity, by reduction in the equity base, thereby leading to long-term increase in shareholders' vlaue; and
• The buyback gives an option to the shareholders holding Equity shares of the company, who can choose to participate and get cash in lieu of Equity shares to be accepted under the Buyback offer or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the buyback offer, without additional investment.